New York, June 12, 2026, 16:45 (EDT)
- Alumis ended the day at $24.15, gaining 15.55%. About 2.25 million shares changed hands, over twice its normal volume.
- Phase 2b LUMUS lupus results are due in the third quarter, set to be the next big event. Alumis aims to file a psoriasis NDA in the fourth quarter.
- Alumis is still running at a loss and doesn’t have any approved products for sale. Most analysts are positive, but the stock is still seen as a high-risk biotech name.
Alumis Inc. (ALMS) jumped 15.55% Friday, finishing at $24.15 on Nasdaq—up $3.25. Volume hit about 2.25 million shares, more than double its typical 1.01 million average. Market cap climbed to $3.08 billion. The stock moved closer to its 52-week high of $30.60, according to Google Finance.
Alumis’ jump is notable because the company, a late-stage biopharma, doesn’t trade on current revenue but on confidence in its main drug, envudeucitinib. Analyst data points to a bullish view: Benzinga shows a consensus Buy rating and a $36.73 target. The most recent calls include Chardan at Buy and $40, Wells Fargo at Overweight and $51, and Guggenheim with Buy and a $34 target.
Bullish bets on Alumis focus on envudeucitinib, an oral TYK2 inhibitor targeting tyrosine kinase 2, an immune-signaling enzyme tied to inflammatory disease. In March, Alumis said its Phase 3 ONWARD1 and ONWARD2 trials in plaque psoriasis delivered PASI 90 responses—meaning 90% improvement on the Psoriasis Area and Severity Index—of 68.0% and 62.1% at 24 weeks. PASI 100, showing complete skin clearance, came in at 41.0% and 39.5% at the same point.
Investors are focused on Alumis’ clinical and regulatory schedule ahead, not Friday’s stock move. The company expects topline data from its potentially pivotal Phase 2b LUMUS trial in systemic lupus erythematosus in the third quarter of 2026. Its planned NDA submission for psoriasis is still set for the fourth quarter. An NDA, or New Drug Application, is the formal request to the FDA for U.S. marketing approval. “We remain on track for our NDA submission in the fourth quarter of this year,” CEO Martin Babler said. GlobeNewswire
Bulls still point to a working case for the stock: late-stage oral psoriasis asset, the chance for a lupus push, and analyst targets sitting above the current price. Alumis says its balance sheet held $569.5 million in cash, cash equivalents and marketable securities at March 31. The company also said it expects cash to cover operating costs and capital spending into the fourth quarter of 2027, letting it get through several important readouts and regulatory events.
The bear case isn’t hard to spot. Alumis posted a net loss of $93.1 million for the first quarter and warned in its 10-Q that it expects to keep losing large sums. The company told investors it doesn’t expect any revenue from product sales unless it gets a product approved and manages to commercialize it. Alumis also has a $300 million at-the-market equity program in place, but as of March 31, it hadn’t issued any shares under the agreement. These programs can dilute existing holders, since new shares would leave current investors owning less of the company.
ALMS soared 15.55% in a day, but the move puts the stock in high-risk biotech territory instead of looking like a clear value play. Late-stage data and bullish analyst calls support ALMS, but most of the valuation rides on key lupus trial results, a successful NDA, an FDA nod and the company’s ability to compete in immunology. For cautious investors, the big Friday rally pushes the risk higher until the next clinical or regulatory update.
